HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Slosberg, E. D. Articles by Caplan, S. L. Search for Related Content PubMed PubMed Citation Articles by Slosberg, E. D. Articles by Caplan, S. L. Social Bookmarking                What's this?

Treatment of Type 2 Diabetes by Adenoviral-Mediated Overexpression of the Glucokinase Regulatory Protein

¹ Novartis Institute for Biomedical Research, Metabolic and Cardiovascular Diseases, Summit, New Jersey
² Genetic Therapy, Inc., Gaithersburg, Maryland

The enzyme glucokinase (GK) plays a central role in glucose homeostasis. Hepatic GK activity is acutely controlled by the action of the GK regulatory protein (GKRP). In vitro evidence suggests that GKRP reversibly binds to GK and inhibits its activity; however, less is known about the in vivo function of GKRP. To further explore the physiological role of GKRP in vivo, we used an E1/E2a/E3-deficient adenoviral vector containing the cDNA encoding human GKRP (Av3hGKRP). High fat diet–induced diabetic mice were administered Av3hGKRP or a control vector lacking a transgene (Av3Null). Surprisingly, the Av3hGKRP-treated mice showed a significant improvement in glucose tolerance and had lower fasting blood glucose levels than Av3Null-treated mice. A coincident decrease in insulin levels indicated that the Av3hGKRP-treated mice had sharply improved insulin sensitivity. These mice also exhibited lower leptin levels, reduced body weight, and decreased liver GK activity. In vitro experiments indicated that GKRP was able to increase both GK protein and enzymatic activity levels, suggesting that another role for GKRP is to stabilize and/or protect GK. These data are the first to indicate the ability of GKRP to treat type 2 diabetes and therefore have significant implications for future therapies of this disease.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				M. Vaxillaire, C. Cavalcanti-Proenca, A. Dechaume, J. Tichet, M. Marre, B. Balkau, P. Froguel, and for the DESIR Study Group The Common P446L Polymorphism in GCKR Inversely Modulates Fasting Glucose and Triglyceride Levels and Reduces Type 2 Diabetes Risk in the DESIR Prospective General French Population Diabetes, August 1, 2008; 57(8): 2253 - 2257. [Abstract] [Full Text] [PDF]

				Diabetes Genetics Initiative of Broad Institute of, R. Saxena, B. F. Voight, V. Lyssenko, N. P. Burtt, P. I. W. de Bakker, H. Chen, J. J. Roix, S. Kathiresan, J. N. Hirschhorn, et al. Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels Science, June 1, 2007; 316(5829): 1331 - 1336. [Abstract] [Full Text] [PDF]

				J. J. Collier and D. K. Scott Sweet Changes: Glucose Homeostasis Can Be Altered by Manipulating Genes Controlling Hepatic Glucose Metabolism Mol. Endocrinol., May 1, 2004; 18(5): 1051 - 1063. [Abstract] [Full Text] [PDF]

				Y. Gao, K. Walder, T. Sunderland, L. Kantham, H. C. Feng, M. Quick, N. Bishara, A. de Silva, G. Augert, J. Tenne-Brown, et al. Elevation in Tanis Expression Alters Glucose Metabolism and Insulin Sensitivity in H4IIE Cells Diabetes, April 1, 2003; 52(4): 929 - 934. [Abstract] [Full Text] [PDF]

				M. Veiga-da-Cunha and E. Van Schaftingen Identification of Fructose 6-Phosphate- and Fructose 1-Phosphate-binding Residues in the Regulatory Protein of Glucokinase J. Biol. Chem., March 1, 2002; 277(10): 8466 - 8473. [Abstract] [Full Text] [PDF]